Repatha, a PCSK9 inhibitor developed by Amgen, generated $585 million in sales in the first quarter of 2024 [1]. This represents a 23% increase compared to the same period in 2023 [1].
How much did Repatha make last year?
In 2023, Repatha recorded total sales of $2.07 billion [2]. This was a 13% increase from the $1.83 billion in sales achieved in 2022 [2].
What is driving Repatha's sales growth?
The growth in Repatha sales is attributed to increased prescription volume, particularly in the United States and Europe [1]. Amgen has seen positive results from its commercial efforts, including the expansion of access and uptake in various markets [1].
How does Repatha compare to other cholesterol-lowering drugs?
Repatha is a PCSK9 inhibitor, a class of drugs that work differently from statins. While statins block cholesterol production in the liver, PCSK9 inhibitors block a protein called PCSK9, which helps remove LDL cholesterol from the bloodstream [3]. Repatha is prescribed for individuals with certain genetic high cholesterol conditions (familial hypercholesterolemia) or those who have had a cardiovascular event and require additional LDL cholesterol lowering [3]. Other PCSK9 inhibitors on the market include Praluent (alirocumab) by Sanofi and Regeneron [4].
When did Repatha's patents expire?
Patent expiry dates can vary depending on the specific patent and region. Information on drug patent expirations, including those for Repatha, is available through resources like DrugPatentWatch.com [5].
What is the mechanism of action for Repatha?
Repatha (evolocumab) is a human monoclonal antibody that inhibits the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein [3]. By binding to PCSK9, Repatha prevents it from binding to the LDL receptor (LDLR) on the surface of liver cells. This inhibition allows more LDL receptors to remain on the liver cell surface, increasing the clearance of LDL cholesterol (often referred to as "bad" cholesterol) from the blood [3].
Are there any risks associated with Repatha?
The most common side effects of Repatha include nasopharyngitis (cold or sore throat), upper respiratory tract infection, and influenza [3]. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider.
Who manufactures Repatha?
Repatha is manufactured by Amgen [1].
What is the pricing of Repatha?
Pricing for Repatha can vary based on insurance coverage, pharmacy, and location. Patients can inquire about potential cost-saving programs or discuss pricing with their healthcare providers.
What is the clinical data supporting Repatha?
Clinical trials have demonstrated Repatha's ability to significantly lower LDL cholesterol levels [3]. For example, the FOURIER trial showed that Repatha, added to statin therapy, reduced the risk of cardiovascular events such as heart attack and stroke in patients with established cardiovascular disease [3].
What are patient concerns regarding Repatha?
Patients often have questions about the effectiveness of Repatha in lowering their cholesterol, potential side effects, the duration of treatment, and how Repatha fits into their overall treatment plan for cardiovascular risk reduction [3]. Cost and insurance coverage are also significant considerations for many patients.
Sources:
[1] https://www.amgen.com/newsroom/press-releases/2024/04/amgen-announces-first-quarter-2024-financial-results
[2] https://www.amgen.com/newsroom/press-releases/2024/02/amgen-announces-fourth-quarter-and-full-year-2023-financial-results
[3] https://www.repathahcp.com/
[4] https://www.drugpatentwatch.com/drugs/praluent
[5] https://www.drugpatentwatch.com/drugs/repatha